Analysis of serum proteomics data identifies a quantitative association between beta-defensin 2 at baseline and clinical response to IL-17 blockade in psoriatic arthritis.

ABSTRACT:

Objectives

Despite several effective targeted therapies, biomarkers that predict whether a patient with psoriatic arthritis (PsA) will respond to a particular treatment are currently lacking.

Methods

We analysed proteomics data from serum samples of nearly 2000 patients with PsA in placebo-controlled phase-III clinical trials of the interleukin-17 inhibitor secukinumab. To discover predictive biomarkers of clinical response, we used statistical learning with controlled feature selection. The top candidate was validated using an ELISA and was separately assessed in a trial of almost 800 patients with PsA treated with secukinumab or the tumour necrosis factor inhibitor adalimumab.

Results

Serum levels of beta-defensin 2 (BD-2) at baseline were found to be robustly assoc

SUBMITTER: Cardner M 

PROVIDER: S-EPMC10277527 | biostudies-literature | 2023 Jun

REPOSITORIES: biostudies-literature